
MEDSIR's ATRACTIB & DEBBRA clinical trials: Promising results to improve the lives of advanced breast cancer patients
The ATRACTIB trial showed significant antitumor activity through a combined therapy, and the DEBBRAH trial had a median overall survival of 13.3 months. SAN ANTONIO, TEXAS, UNITED STATES, December 8, 2023 /EINPresswire.com/ -- MEDSIR, a global …